Hospital
Baptist Memorial Hospital-Calhoun INC
Baptist Memorial Hospital-Calhoun INC was paid $7.27M by Medicaid between Jan 2018 and Dec 2024, across 95 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoBAPTIST MEMORIAL HOSPITAL-CALHOUN INC
CALHOUN CITY, MS 38916
CALHOUN CITY, MS 38916
33aNPI1881142461assigned 09/13/2016
33bProvider typeCritical Access Hospital
28Total paid$7.27M
24GClaims229,569
24DCodes billed95
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#8 of 32
Median peer was paid$3.94M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,369 | $1.06M | |
| 2019 | 28,830 | $1.12M | |
| 2020 | 26,405 | $873K | |
| 2021 | 33,478 | $1.06M | |
| 2022 | 43,402 | $1.08M | |
| 2023 | 39,460 | $1.16M | |
| 2024incomplete | 26,625 | $919K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 8,129 | 6,348 | $1.23M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 17% | 48,334 | 3,899 | $1.23M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 7,542 | 6,224 | $983K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 10% | 38,276 | 2,584 | $760K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 3,806 | 3,066 | $683K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 3.9% | 4,173 | 713 | $284K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 1,980 | 1,566 | $174K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.3% | 4,996 | 3,335 | $169K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.2% | 4,989 | 904 | $159K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.1% | 4,400 | 3,533 | $152K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 3,998 | 2,881 | $130K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 1,574 | 1,187 | $120K |
83 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 2,342 | $99K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 1,346 | $89K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.2% | 8,182 | $85K |
| G0378 | Hospital observation service, per hour | 1.1% | 295 | $81K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 7,455 | $77K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 3,974 | $74K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 860 | $73K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,197 | $62K |
| 80053 | Comprehensive metabolic panel | <1% | 7,087 | $49K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,693 | $44K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,397 | $43K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,316 | $38K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 218 | $34K |
| 83880 | <1% | 1,586 | $31K | |
| 97129 | <1% | 596 | $26K | |
| 84484 | <1% | 3,434 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 950 | $22K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,556 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 221 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 108 | $17K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 215 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,221 | $15K |
| 97162 | <1% | 497 | $15K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 188 | $12K |
| 83605 | <1% | 2,002 | $10K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 161 | $10K |
| 87807 | <1% | 983 | $9K | |
| 81001 | <1% | 4,070 | $8K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 49 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 118 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,482 | $6K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 118 | $6K |
| 83735 | <1% | 1,733 | $6K | |
| 97116 | <1% | 688 | $6K | |
| 82553 | <1% | 444 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 454 | $4K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 133 | $4K |
| 97130 | <1% | 148 | $3K | |
| 83690 | <1% | 755 | $3K | |
| 87040 | <1% | 531 | $3K | |
| 85027 | <1% | 737 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 147 | $3K |
| 82550 | <1% | 465 | $3K | |
| 97014 | <1% | 440 | $3K | |
| 74018 | <1% | 69 | $2K | |
| A9270 | Non-covered item or service | <1% | 2,589 | $2K |
| 73560 | <1% | 40 | $2K | |
| 82150 | <1% | 332 | $2K | |
| 97165 | <1% | 88 | $2K | |
| 81025 | <1% | 331 | $2K | |
| 80305 | <1% | 272 | $2K | |
| 97161 | <1% | 53 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,376 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,105 | $2K |
| 85610 | <1% | 457 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 95 | $856.99 |
| 85730 | <1% | 124 | $688.21 | |
| 73610 | <1% | 21 | $667.80 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 112 | $533.80 |
| 73130 | <1% | 14 | $513.28 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,792 | $484.02 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 109 | $481.98 |
| 96376 | <1% | 71 | $328.79 | |
| 80061 | Lipid panel | <1% | 15 | $250.44 |
| 85379 | <1% | 51 | $195.58 | |
| 80069 | <1% | 170 | $193.41 | |
| 82803 | <1% | 19 | $186.84 | |
| 86140 | <1% | 49 | $173.87 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,059 | $130.45 |
| 82375 | <1% | 19 | $117.94 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 117 | $104.01 |
| 83050 | <1% | 19 | $70.78 | |
| 81003 | <1% | 20 | $43.91 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 22 | $30.37 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 639 | $26.55 |
| 85007 | <1% | 13 | $20.64 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 220 | $9.67 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 241 | $0.28 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 224 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 258 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 273 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 274 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP/CORP SECRETARY)
Parent organizationBAPTIST MEMORIAL HEALTH CARE CORP.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.